

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Zeldis

Confirmation No.: 2021

Application No: 10/693,794

Group Art Unit: 1623

Filed: October 23, 2003

Examiner: OLSON, Eric

For: METHODS FOR TREATMENT
OF COMPLEX REGIONAL PAIN
SYNDROME USING 3-(4-AMINO-
1-OXO-1,3-DIHYDRO-ISOINDOL-2-YL)-
PIPERIDINE-2,6-DIONE

Jones Day Docket No.: 9516-076-999
CAM: 501872-999075

REQUEST FOR CORRECTED FILING RECEIPT

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

This is a request to correct the Filing Receipt in the above-referenced application. The basis for the correction is an error in the title of the invention as listed in PAIR. Specifically, Applicant requests that a corrected Filing Receipt be issued reflecting the following change:

Please replace the word “3-(4-Amino-1,3-Dihydro-Isoindol-2-YL)-Piperidine-2,6-Dione” with “3-(4-Amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione” in the title of the invention.

Applicant points out that, in response to the Office Action dated October 23, 2006, the title of the invention was amended to recite “Methods for Treatment of Complex Regional Pain Syndrome Using 3-(4-Amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione.” Therefore, the error in the title of the invention occurred on the part of the PTO.

Enclosed herewith is a copy of the marked up Filing Receipt. Applicants request that a corrected Filing Receipt be provided reflecting the above changes.

We believe that no fee is required with this submission, however, if it is found that a fee is necessary, the Commissioner is hereby authorized to charge any

additional required fee under 37 C.F.R. § 1.17, or any other required fee, or any credits, to Jones Day Deposit Account No. 503013.

Respectfully submitted,

Date: July 16, 2008



Mark D. Kafka (Reg. No. 59,569)
For Anthony M. Insogna (Reg. No. 35,203)
JONES DAY
222 East 41st Street
New York, NY 10017
Tel. (212) 326-3778




UNITED STATES PATENT AND TRADEMARK OFFICE


UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY.DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/693,794 ✓	10/23/2003 ✓	1644 ✓	878	9516-076-999		26	3

20583
 JONES DAY
 222 EAST 41ST ST
 NEW YORK, NY 10017



CONFIRMATION NO. 2021 ✓
 FILING RECEIPT



OC000000016241870

Date Mailed: 06/10/2005

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please mail to the Commissioner for Patents P.O. Box 1450 Alexandria Va 22313-1450. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

- Jerome B. Zeldis, Princeton, NJ;
- Herbert Faleck, West Orange, NJ;
- Donald C. Manning, Bloomsbury, NJ;

Power of Attorney: None

Domestic Priority data as claimed by applicant

This appin claims benefit of 60/421,003 10/24/2002 ✓

Foreign Applications

If Required, Foreign Filing License Granted: 06/09/2005

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is **US10/693,794**

Projected Publication Date: 09/15/2005

Non-Publication Request: No

Early Publication Request: No

Title

Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain for Treatment of Complex Regional Pain Syndrome Using 3-(4-Amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione

Preliminary Class 424

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).